Manzamine A

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Manzamine A 是一种口服活性 β-carboline 生物碱，抑制 GSK-3β 和 CDK-5 的 IC50 值为 10.2 μM 和 1.5 μM。Manzamine A 靶向胰腺癌细胞的 vacuolar ATPases 并抑制自噬 (autophagy)。Manzamine A 具有抗疟和抗癌活性。Manzamine A 对 HSV-1 具有较强的活性。

Manzamine A, an orally active beta-carboline alkaloid, inhibits specifically GSK-3β and CDK-5 with IC50s of 10.2 μM and 1.5 μM, respectively. Manzamine A targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Manzamine A has antimalarial and anticancer activities. Manzamine A also shows potent activity against HSV-1.

Manzamine A (50 and 100 mol/kg, p.o. or i.p.) inhibits the growth of the rodent malaria parasite Plasmodium berghei in infected mice.Manzamine A (8 mg/kg, i.p., daily for 8 consecutive days) prolongs the survival of SW mice to 20 days.Animal Model:Plasmodium berghei in infected mice Dosage:50 or 100 mol/kg Administration:Intraperitoneal injection (i.p.) or oral administration (p.o.) Result:Inhibited the growth of the rodent malaria parasite Plasmodium berghei.Prolonged the survival of highly parasitaemic mice.

Manzamine A (5-50 μM, 18 h) decreases tau phosphorylation, measured with ELISA.Manzamine A (10 μM) inhibits yeast S. cerevisiae growth by 30%.Manzamine A displays a few enlarged vacuoles in yeast.Manzamine A (2.5-10 μM, 24 h) increases acidity in pancreatic cancer cells and non-malignant Vero cells.Manzamine A (1 μM, 24 h) inhibits HSV-1 infection in SIRC cells.Manzamine A shows antimalarial activity with an IC50 of 8.0 nM (D6 clone) and 11 nM (W2 clone).Cell Viability Assay Cell Line:SIRC cell Concentration:0.1, 0.5, 1, 2, 3, 5, and 10 μMv Incubation ime:72 hv Result:Inhibited SIRC cell viability with an IC50 of 5.6 μM.

———

Others

Other Targets

———

———

———

104196-68-1

548.775

C36H44N4O

>98% (HPLC)

DMSO : 10 mg/mL (18.22 mM; ultraphonic; )

———

———

(-20℃)

With Ice Pack

≥ 2 years